Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors
December 04 2019 - 4:05PM
Business Wire
- Former CEO of Array BioPharma Brings
Expertise in Oncology Drug Development and Commercialization -
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage
biopharmaceutical company addressing key mechanisms of tumor drug
resistance, today announced that it has appointed Ron Squarer to
its Board of Directors. Mr. Squarer served as Chief Executive
Officer and a member of the Board of Directors of Array BioPharma,
Inc. (Array) from 2012 until its acquisition by Pfizer Inc.
(Pfizer) in August 2019 following the successful commercial
launches of both Braftovi® and Mektovi®.
“Ron brings over two decades of experience in the
biopharmaceutical industry to our Board of Directors, with a focus
and expertise in oncology drug development, commercialization, and
new product launches,” said Steve Hoerter, President and Chief
Executive Officer of Deciphera. “We look forward to his valuable
insights as we build our commercial organization and advance our
pipeline of novel product candidates.”
“I am excited to join Deciphera’s accomplished board members and
impressive leadership team to help guide the Company in its
progression to a fully integrated biopharmaceutical company,” said
Mr. Squarer. “I believe that Deciphera is well-positioned to
deliver on its mission to improve the lives of cancer patients, and
look forward to contributing to the Company’s success.”
During his seven-year tenure at Array, Mr. Squarer executed a
research, development, and commercialization strategy focused on
oncology that culminated in the acquisition of Array by Pfizer for
$11.8 billion. Before joining Array, Mr. Squarer held positions of
increasing responsibility with Hospira, Inc., a global
pharmaceutical and medical device company. As Senior Vice President
and Chief Commercial Officer at Hospira, he was responsible for
delivering $4 billion in annual revenue. Mr. Squarer joined Hospira
from Mayne Pharma, where he served as Senior Vice President, Global
Corporate and Business Development, when Mayne was sold to Hospira
in 2007. Before Mayne Pharma, Mr. Squarer held leadership roles at
both Pfizer (focused on oncology), and SmithKline Beecham
Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe. He
currently serves as a member of the Board of Directors of
Retrophin, Inc. Mr. Squarer earned an MBA from the Kellogg School
of Management, Northwestern University, and a bachelor’s degree in
biochemistry from the University of California, Berkeley.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical
company focused on improving the lives of cancer patients by
addressing key mechanisms of drug resistance that limit the rate
and/or durability of response to existing cancer therapies. Our
small molecule drug candidates are directed against an important
family of enzymes called kinases, known to be directly involved in
the growth and spread of many cancers. We use our deep
understanding of kinase biology together with a proprietary
chemistry library to purposefully design compounds that maintain
kinases in a “switched off” or inactivated conformation. These
investigational therapies comprise tumor-targeted agents designed
to address therapeutic resistance causing mutations and
immuno-targeted agents designed to control the activation of
immunokinases that suppress critical immune system regulators, and
agents designed to inhibit reprogramming of cancer cell metabolism.
We have used our platform to develop a diverse pipeline of
tumor-targeted, immuno-targeted, and metabolism-targeted drug
candidates designed to improve outcomes for patients with cancer by
improving the quality, rate and/or durability of their responses to
treatment.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding our expectations regarding future growth and scale of
operations, potential growth into a commercial company and the
potential of our pipeline product candidates to improve the lives
of patients with cancer. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management’s current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks and uncertainties related to the delay of any
current or planned clinical studies or the development of our
product candidates, including ripretinib, our ability to
successfully demonstrate the efficacy and safety of our product
candidates including in later-stage studies, the preclinical and
clinical results for our product candidates, which may not support
further development of such product candidates, the possibility
that results experienced in early, preliminary, top-line or initial
data, may not be indicative of the results experienced in final
data, our ability to timely complete and prepare the information
required for and file an NDA for ripretinib, the fact that receipt
of a breakthrough therapy designation for a product candidate, such
as ripretinib, may not result in us receiving any of the benefits
of such designation, our ability to manage and our reliance on
third parties such as our third party drug substance and drug
product contract manufacturers, actions of regulatory agencies, any
or all of which may affect the initiation, timing and progress of
clinical studies and the timing of and our ability to obtain
regulatory approval, if at all, and make our investigational drugs
available to patients, and other risks identified in our SEC
filings, including our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2019, and subsequent filings with the
SEC. We caution you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. We disclaim any obligation to publicly update or revise
any such statements to reflect any change in expectations or in
events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Any forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191204005779/en/
Investor Relations: Jen Robinson Deciphera Pharmaceuticals, Inc.
jrobinson@deciphera.com 781-906-1112 Media: David Rosen Argot
Partners David.Rosen@argotpartners.com 212-600-1902
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Sep 2023 to Sep 2024